Skip to main content

Market Overview

TransEnterix Announces Senhance US Sale Agreement With Florida Hospital

Share:

First Agreement to Purchase Senhance Surgical System in the US

TransEnterix, Inc. (NYSE:TRXC), a medical device company that
is pioneering the use of robotics to improve minimally invasive surgery,
today announced that Florida Hospital entered into an agreement to
purchase the Company's Senhance Surgical Robotic System.

The Florida Hospital Orlando campus will be home to the first commercial
unit of the Senhance Surgical System to be installed in the United
States.

Now available in the United States, the recently FDA-cleared Senhance
Surgical System represents an innovative technology designed to assist
surgeons in performing minimally invasive surgery. The system features
multiple robotic arms that are controlled by a surgeon seated
comfortably at a console. The surgeon controls small surgical
instruments with robotic precision while at the same time moving a small
scope that tracks the eye movement of the surgeon. The Senhance is the
first surgical robotic system to offer the security of haptic force
feedback that allows surgeons to feel the forces the instruments
generate when handling delicate tissue. The Senhance represents a new
era of digital laparoscopy designed to support responsible economics for
the hospital, patient and today's value-based healthcare system.

"We are pleased to announce our first US sale of the Senhance Surgical
System," said Todd M. Pope, President and CEO at TransEnterix. "Florida
Hospital is a global leader in the application of next generation
technologies to care for patients. It's fitting that Florida Hospital
will be the first in the United States to adopt this technology for
patient care."

"The digital operating room of the future has arrived, and our surgeons
will continue to be leaders in applying robotic technology, like the
Senhance, to benefit our patients across a full range of procedures and
specialties," said Dr. Steve Eubanks, surgeon and Executive Medical
Director for the Institute for Surgical Advancement at Florida Hospital.
"Our team of clinicians selected the Senhance Surgical System to further
our minimally invasive offerings. We believe this robotic system will
support our surgeons in maximizing their precision and control during
procedures while minimizing costs."

About Florida Hospital

Florida Hospital is a member of Adventist Health System, which operates
45 hospitals in 9 states, making it one of the largest not-for-profit
healthcare systems in the United States, caring for more than 5 million
patients annually. Florida Hospital continues to be at the forefront of
health-care innovation. In addition to the Florida Hospital Institute
for Surgical Advancement, it's also home to the Florida Hospital
Nicholson Center, a facility specializing in training surgeons from
around the globe on the latest surgical technology and techniques, and
the Global Robotics Institute, a world leader in the robotic-assisted
treatment of prostate cancer.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options in today's value-based healthcare environment. The
company is focused on the commercialization of the Senhance
Surgical Robotic System, a multi-port robotic system that brings the
advantages of robotic surgery to patients while enabling surgeons with
innovative technology such as haptic feedback and eye sensing camera
control. The company is also developing the SurgiBot™ System, a
single-port, robotically enhanced laparoscopic surgical platform. The
Senhance Surgical Robotic System is available for sale in the US, the EU
and select other countries. For more information, visit the TransEnterix
website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the Senhance
Surgical Robotic System and our current regulatory and commercialization
plans for this product. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are subject to
risks and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the Senhance Surgical Robotic System
will benefit Florida Hospital's patients and whether the Senhance
Surgical Robotic System will support Florida Hospital's surgeons in
maximizing their precision and control during procedures while
minimizing costs. For a discussion of the risks and uncertainties
associated with TransEnterix's business, please review our filings with
the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K filed on March 7, 2017 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as of
the date of this press release and speak only as of the origination date
of this press release. We undertake no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com